Rho guanine nucleotide exchange factor 12Genealiases: LARG · PRO2792
Q-omics provides the consensus-scored ARHGEF12 profile across patient tissues and cancer cell-line models. ARHGEF12 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, ARHGEF12 is differentially expressed in 13, with the highest sampling consensus in KIRC. Additionally, ARHGEF12 protein abundance shows 21,194 significant protein co-abundance associations, with the highest sampling consensus in BRCA. Together, these results highlight KIRC, and BRCA as cancer lineages where ARHGEF12 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for ARHGEF12 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes ARHGEF12 survival associations across molecular data types. ARHGEF12 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (7) and mass-spec protein abundance (5). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible ARHGEF12 RNA expression–survival associations across cancer types. High ARHGEF12 expression shows unfavorable associations in BLCA, ACC and PAAD, but favorable associations in KIRC, HNSC and UCS. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for ARHGEF12 RNA expression.
This table summarizes ARHGEF12 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 13, while mass-spec protein shows differences in 6. The strongest signals are observed in KIRC for RNA and HNSC for protein.
This table ranks reproducible tumor–normal expression differences for ARHGEF12. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. ARHGEF12 shows lower tumor expression in KIRC, LUSC, KIRP, KICH and COAD and higher tumor expression in HNSC. The KIRC box plot shows higher ARHGEF12 RNA expression in normal versus tumor tissue (log2 FC = −0.515, t-test p = .001).
This table shows molecular features associated with ARHGEF12 in patient tissues and cancer cell lines. In patient samples, ARHGEF12 shows the broadest associations at the RNA and protein expression levels, with BRCA recurring as the lineage with the largest associated feature set. In cancer cell lines, ARHGEF12 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LIVER, while CRISPR and shRNA rows add functional-dependency signals in CNS and LARGE_INTESTINE.
